November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at ...

Here is a breakdown of the information Valneva Se presented to its investors. Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for ...

Valneva (VALN) has released an update. Valneva SE has reported €116.6 million in total revenues for the first nine months of 2024, with a notable turnaround to a €24.7 million net profit, driven by ...

With a promising pipeline, including the S4V2 Shigella vaccine candidate, Valneva is poised for growth and strategic expansion. TipRanks is the most comprehensive data set of sell side analysts ...

Valneva’s sales in the first nine months of 2024 were €112.5 million compared to €106.1 million (€100.4 million excluding final COVID-19 vaccine sales) in the first nine months of 2023.

Here is a breakdown of the information Valneva Se presented to its investors. Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for ...

Valneva SE (INRLF) is on track with its Lyme Disease vaccine program, with regulatory filings expected in 2026 and potential approval in 2027. The company has achieved FDA fast track designation ...

The vaccine contains a strain of chikungunya virus that has been attenuated. IXCHIQ comes from Valneva Canada and it is ...

that we are approaching next year really a turning point in Valneva's evolution. We are targeting sustained profitability from 2027 onwards, driven by success of the Lyme disease vaccine program ...

Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage ...